Aethlon Medical Submits Avian Flu Treatment Grant
April 12 2006 - 7:00AM
Business Wire
Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing
therapeutic devices for infectious disease, announced today that it
has submitted an Avian Flu-related grant application entitled,
"Extracorporeal Treatment of H5N1 Bird Flu Viral Sepsis." The grant
was submitted to the National Institutes of Health (NIH) to be
directed to the National Institute of Allergy and Infectious
Disease (NIAID) as a Phase I Small Business Innovation Grant. The
grant application discusses the deployment of the Aethlon
Hemopurifier(TM) as a therapy to clear inflammatory cytokines, H5N1
Avian Flu virus and viral fragments that stimulate viral sepsis.
Grant collaborators include Dr. Leo L.M. Poon, Assistant Professor
at the University of Hong Kong, Department of Microbiology, and Dr.
Kevin Gilligan, Senior Scientist at Commonwealth Biotechnologies.
There is no assurance that Aethlon will derive grant income related
to this research initiative. About Aethlon Medical Aethlon Medical
is developing the first medical device to treat infectious disease.
The device, known as the Hemopurifier(TM), is a broad-spectrum
treatment countermeasure against drug and vaccine resistant
bioweapons, naturally evolving pandemic threats such as H5N1 Avian
Flu and chronic infectious disease targets, including Hepatitis-C
(HCV) and the Human Immunodeficiency Virus (HIV). Aethlon has also
initiated research on a second generation Hemopurifier(TM) that
targets the capture of growth factors inherent in the spread of
Cancer. More information on Aethlon Medical and the
Hemopurifier(TM) technology can be found at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of
its products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product
liability exposure, uncertainty of market acceptance, competition,
technological change and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings.